Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-24T16:23:29.078Z Has data issue: false hasContentIssue false
  • English
  • Français

Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)

Published online by Cambridge University Press:  02 January 2015

Neil Fishman ,
Society for Healthcare Epidemiology of America ,
Infectious Diseases Society of America  and
Pediatric Infectious Diseases Society
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Antimicrobial resistance has emerged as a significant healthcare quality and patient safety issue in the twenty-first century that, combined with a rapidly dwindling antimicrobial armamentarium, has resulted in a critical threat to the public health of the United States. Antimicrobial stewardship programs optimize antimicrobial use to achieve the best clinical outcomes while minimizing adverse events and limiting selective pressures that drive the emergence of resistance and may also reduce excessive costs attributable to suboptimal antimicrobial use. Therefore, antimicrobial stewardship must be a fiduciary responsibility for all healthcare institutions across the continuum of care. This position statement of the Society for Healthcare Epidemiology of America, the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society of America outlines recommendations for the mandatory implementation of antimicrobial stewardship throughout health care, suggests process and outcome measures to monitor these interventions, and addresses deficiencies in education and research in this field as well as the lack of accurate data on antimicrobial use in the United States.

Type
Shea/Idsa/Pids Policy Statement
Information
Infection Control & Hospital Epidemiology , Volume 33 , Issue 4: Special Topic Issue: Antimicrobial Stewardship , April 2012 , pp. 322 - 327
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2012

References

1. Penicillin finder assays its future. New York Times. 26 June 1945:21.Google Scholar
2. Spink, WW, Ferris, V. Quantitative action of penicillin inhibitor from penicillin-resistant strain of Staphylococcus . Science 1945; 102:221–223.CrossRefGoogle Scholar
3. Barrett, FF, McGehee, RF, Finland, M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital. N Engl J Med 1968; 279:441–448.CrossRefGoogle ScholarPubMed
4. Centers for Disease Control and Prevention NNIS System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000; issued June 2000. Am J Infect Control 2000;28:429–448.CrossRefGoogle Scholar
5. Herold, BC, Immergluck, LC, Maranan, MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593–598.CrossRefGoogle ScholarPubMed
6. Naimi, TS, LeDell, KH, Como-Sabetti, K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976–2984.CrossRefGoogle ScholarPubMed
7. Deleo, FR, Otto, M, Kreisworth, BN, Chambers, HF. Community-associated meticillin-resistant Staphylococcus aureus . Lancet 2010;375:1557–1568.CrossRefGoogle ScholarPubMed
8. Lynch, JP 3rd, Zhanel, GG. Streptococcus pneumoniae, epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010;16:217–225.Google ScholarPubMed
9. Deguchi, T, Nakane, K, Yasuda, M, Maeda, S. Emergence and spread of drug resistant Neisseria gonorrhoeae . J Urol 2010;184:851–858.CrossRefGoogle ScholarPubMed
10. Parry, CM, Threlfall, EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 2008;21:531–538.Google Scholar
11. Jacobson, KR, Tierney, DB, Jeon, CY, Mitnick, CD, Murray, MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6–14.CrossRefGoogle ScholarPubMed
12. Bonten, MJ, Willems, R, Weinstein, RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001;1:314–325.CrossRefGoogle ScholarPubMed
13. Chavers, LS, Moser, SA, Benjamin, WH, et al. Vancomycin-resistant enterococci: 15 years and counting, J Hosp Infect 2003; 53:159–171.CrossRefGoogle Scholar
14. Hiramatsu, K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147–155.CrossRefGoogle ScholarPubMed
15. Nordmann, P, Cuzon, G, Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228–236.CrossRefGoogle ScholarPubMed
16. Ho, J, Tambyah, PA, Paterson, DL. Multiresistant gram-negative infections: a global perspective. Curr Opin Infect Dis 2010;23:546–553.Google Scholar
17. Oteo, J, Pérez-Vázquez, M, Campos, J. Extended-spectrum beta-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010;23:320–326.CrossRefGoogle ScholarPubMed
18. Garnacho-Montero, J, Amaya-Villar, R. Multiresistant Acineto-bacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010;23:332–339.CrossRefGoogle Scholar
19. Zavascki, AP, Carvalhaes, CG, Picāo, RC, Gales, AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71–93.CrossRefGoogle ScholarPubMed
20. Falagas, ME, Rafailidis, PI, Matthaiou, DK, Virtzili, S, Nikita, D, Michalopoulos, A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008;32:450–454.CrossRefGoogle Scholar
21. Chen, LF, Chopra, T, Kaye, KS. Pathogens resistant to antibacterial agents. Infect Dis Clin N Am 2009;23:817–845.CrossRefGoogle ScholarPubMed
22. Rice, LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009;12:476–481.CrossRefGoogle ScholarPubMed
23. Boucher, HW, Talbot, GH, Bradley, JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12.CrossRefGoogle ScholarPubMed
24. Lautenbach, E, Weiner, MG, Nachamkin, I, Bilker, WB, Sheridan, A, Fishman, NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893–900.Google Scholar
25. Roberts, RR, Hota, B, Ahmad, I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49:1175–1184.CrossRefGoogle Scholar
26. Patel, G, Huprikar, S, Factor, SH, Jenkins, SG, Calfee, DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099–1106.Google Scholar
27. Filice, GA, Nyman, JA, Lexau, C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010;31:365–373.CrossRefGoogle ScholarPubMed
28. Mauldin, PD, Saigado, CD, Hansen, IS, Durup, DT, Bosso, JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 2010;54:109–115.Google Scholar
29. Infectious Diseases Society of America. The 10 × 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081–1083.CrossRefGoogle Scholar
30. Infectious Diseases Society of America. Antimiaobial resistance. http://www.idsociety.org/AR_Policy/. Accessed October 27, 2010.Google Scholar
31. Shlaes, DM, Gerding, DN, John, JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275–291.CrossRefGoogle Scholar
32. Shlaes, DM, Gerding, DN, John, JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584–599.Google Scholar
33. Dellit, TH, Owens, RC, McGowan, JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.Google Scholar
34. Spellberg, B, Blaser, M, Guidos, RJ, et al for the Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52(suppl 5): S397–S428.Google ScholarPubMed
35. Department of Health and Human Services. HHS action plan to prevent healthcare-associated infections, http://www.hhs.gov/ash/initiatives/hai/actionplan/index.html. Accessed October 27, 2010.Google Scholar
36. Gilbert, DN, Spellberg, B, Bartlett, JG for the Infectious Diseases Society of America. Position paper: an unmet medical need: rapid molecular diagnostic tests for respiratory tract infections. Clin Infect Dis 2011;52(suppl 4):S384–S395.Google Scholar
37. Gilbert, DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010;48:2325–2329.CrossRefGoogle ScholarPubMed